NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Entry into a Material Definitive Agreement

NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

Underwriting Agreement

On November6, 2018, Neos Therapeutics,Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald& Co., as representative of the several underwriters listed therein (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 17,391,304 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a public offering price of $2.30 per Share (the “Offering Price”), before underwriting discounts and commissions. to the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,608,695 shares of Common Stock. The gross proceeds to the Company, before deducting the underwriting discounts and estimated expenses associated with the Offering payable by the Company, are expected to be approximately $40 million (assuming the Underwriters do not exercise their option to purchase additional shares). The closing of the Offering is expected to occur on or about November8, 2018, subject to the satisfaction of customary closing conditions.

The Shares are being offered and sold to a prospectus dated August12, 2016 and a prospectus supplement dated November6, 2018,in connection with a takedown from the Company’s shelf registration statement on FormS-3 (Registration No.333-212809) (the “Registration Statement”), which the U.S. Securities and Exchange Commission declared effective on August12, 2016.

The Underwriting Agreement contains customary representations, warranties, covenants, conditions to closing, indemnification and other obligations of the parties and termination provisions.

A copy of the legal opinion of Goodwin Procter LLP, relating to the validity of the Shares issued in the Offering, is filed as Exhibit5.1 to this Current Report on Form8-K and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Underwriting Agreement, which is included as Exhibit1.1 to this Current Report on Form8-K and incorporated by reference herein.

The Underwriting Agreement has been filed with this Current Report on Form8-K to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, and were solely for the benefit of the parties to such agreement.

Item 8.01. Other Events.

On November5, 2018, the Company issued a press release announcing the commencement of the Offering. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

On November6, 2018, the Company issued a press release announcing its entry into the Underwriting Agreement. A copy of the press release is attached hereto as Exhibit99.2 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


Neos Therapeutics, Inc. Exhibit
EX-1.1 2 a18-39554_5ex1d1.htm EX-1.1 Exhibit 1.1   NEOS THERAPEUTICS,…
To view the full exhibit click here


Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

An ad to help with our costs